Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00370513
Status:
COMPLETED
Last Update Posted:
2017-11-17
First Post:
2006-08-29
Brief Title:
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase I Open-Label Dose-Escalation Multi-Center Study or Pazopanib GW786034 in Adult Patients With Hepatocellular Cancer
Status:
COMPLETED
Status Verified Date:
2017-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib The effect of pazopanib in patients with liver cancer are unknown This study is designed to evaluate the safety tolerability and best dose of pazopanib to be given to patient with liver cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None